Cellular Biotechnology Lab
@LAB_BIOC
Cellular Biotechnology Lab at ISCIII Pediatric Cancer / Advanced Therapy / Immunotherapy https://cellularbiotechnol.wixsite.com/bioclab
Hoy arranca la jornada principal del Encuentro Internacional sobre Terapias Avanzadas, que celebramos en nuestro campus de Majadahonda. @red_terav Más de 1️⃣0️⃣0️⃣ expertos se reúnen para compartir avances en terapias y salas blancas al servicio de los pacientes.
El Instituto de Salud Carlos III (ISCIII) acoge un encuentro internacional sobre terapias avanzadas. Organizado por el #IIER, con el apoyo de la Red Española de terapias Avanzadas (Red TERAV+ ISCIII). isciii.es/documents/d/gu… @JavierGC280 @l_marinas
Join us May 28 at ISCIII Majadahonda (Madrid, Spain) 🏨for the Workshop on Adoptive Cell Therapies — dive into the latest on CAR-T and adoptive therapies 💉🧬 Free registration via email: [email protected] Don't miss out!"
El 28 de mayo se celebra el 🔬 Workshop on Adoptive Cell Therapies en el Campus de Majadahonda del @SaludISCIII para compartir las últimas novedades en terapias celulares adoptivas y CAR-T 💉 📧 ¡Y es totalmente gratuito! Regístrate vía email a [email protected]
🔬 Workshop on Adoptive Cell Therapies! 🔬 Open scientific workshop on May 28, 2025, hosted at the Majadahonda Campus of ISCIII (Madrid-Spain). 🎟️ Free access — but registration is required via email: [email protected]
Coming soon, see you in Madrid (Majadahonda) !!!
🧬 3rd INTERNATIONAL WORKSHOP on ADVANCED THERAPIES– register! lnkd.in/d2zgCtdu 🏬 We are pleased to host this event at ISCIII, on our Majadahonda campus @SaludISCIII 💡 Cutting-edge science. A must-attend event for professionals in cell & gene therapy manufacturing
In the pilot phase, no clinical responses were observed in 18 patients unselected TILs. However, when TILs were selected for neoantigen recognition, 3 responses were seen in 39 patients (7.7%). Pembrolizumab was added, and 8 objective responses were seen in 34 patients (23.5%)
Osteosarcoma remains a highly aggressive bone malignancy with limited therapeutic options, necessitating novel treatment strategies. Minireview: frontiersin.org/journals/immun…
T cell receptor precision editing of regulatory T cells for celiac disease. Authors generated gluten- reactive HLA- DQ2.5–restricted CD4+ engineered eTregs. e Tregs hold therapeutic potential for restoring gluten tolerance in their mice model. science.org/doi/epdf/10.11…
La inversión en ciencia es rentable. Barcelona: un ejemplo a seguir 👇
Hace 20 años que creamos nuestra Fundación. Hoy nos unimos a la UAM para seguir apoyando la investigación, los tratamientos y la formación en Oncología Pediátrica Siempre agradecido de como me acogieron en el HNJS y los excelentes médicos que conocí y con los que sigo colaborando
La @UAM_Madrid y @CatedraUAMFOI presentan una cátedra pionera en el ámbito de la #salud infantil, que promoverá la #investigación, formación y divulgación en el campo de las enfermedades #oncohematológicas que afectan a niños y adolescentes. Más Info: fuam.es/noticias/nace-…
Methyltransferases EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models Treated tumors showed upregulation of genes related to adhesion, B cell activation, and inflammatory responses, and increased avidity to CAR-T cell.com/cancer-cell/ab…
Clonal expansion of CD8+ T cells is an immunological driver of bispecific T cell engagers (TCE) Naive T cells require additional MHC class I signal and differentiate upon TCE activation Exhausted CD8+ clones predicts response failure in multiple myeloma cell.com/cancer-cell/fu…
Generation of allogenic CAR invariant natural killer T (CAR-NKT) cells from HSC. Anti-CD33 CAR-NKT cells exhibit strong BM homing and effectively target AML and MDS blasts. TCR-CD1d and NK receptors help in the elimination of leukemic stem cells. nature.com/articles/s4146…
